SEC Company Response from ORAGENICS INC (OGEN) (CIK 0001174940) (OGEN) — Apr 25, 2013
ORAGENICS INC (OGEN) (CIK 0001174940)
Date: April 25, 2013 · CIK: 0001174940 · Accession: 0001193125-13-174548
AI Filing Summary & Sentiment
Reasoning
File numbers found in text: 333-183685
Referenced dates: April 25, 2013
Letter
Via Edgar United States Securities and Exchange Commission Re: Oragenics, Inc. Post-Effective Amendment No. 1 on Form S-3 to a Registration Statement on Form S-1 File No. 333-183685
Dear Mr. Riedler:
On behalf of Oragenics, Inc. (the “Company”), set forth below are responses to the Staff of the Division of Corporation Finance’s comment letter dated April 25, 2013, with respect to the Company’s Post-Effective Amendment No. 1 on Form S-3 to its Registration Statement on Form S-1 (333-183685). For your convenience, the Staff’s comments are set forth in bold and followed by the Company’s response.
Comments
Information Incorporated by Reference, page 38
1. We note that your registration statement incorporates by reference your annual report on Form 10-K for the year ended December 31, 2012. This filing does not contain the Part III information that is required by Form 10-K. Please amend your registration statement, amend your Form 10-K filing, or file your definitive proxy statement to include the required Part III information. Your filing must be complete before we take final action on the registration statement.
Jeffrey Riedler
Securities and Exchange Commission
April 25, 2013
Page 2
Response:
The Company expects to timely file its definitive proxy statement on April 29, 2013 which contains the Part III information of the Form 10-K. Thereafter, the Company believes its filing would be complete.
* * * * *
Should you have any questions or clarifications of the matters raised in this letter please contact the undersigned at (813) 229-7600.
Sincerely,
/s/ Mark A. Catchur
Show Raw Text
CORRESP
1
filename1.htm
Correspondence
Bank of America Plaza
813.229.7600
101 East Kennedy Boulevard
813.229.1660 fax
Suite 2800
Tampa, Florida 33602
www.slk-law.com
MARK A. CATCHUR
(813) 227-2264
mcatchur@slk-law.com
April 25, 2013
Via
Edgar
Jeffrey Riedler, Division of Corporation Finance
United States Securities and Exchange Commission
100 F Street
Washington, DC 20549
Re:
Oragenics, Inc.
Post-Effective
Amendment No. 1 on Form S-3 to a Registration Statement on
Form S-1
File No. 333-183685
Dear
Mr. Riedler:
On behalf of Oragenics, Inc. (the “Company”), set forth below are responses to the Staff of the
Division of Corporation Finance’s comment letter dated April 25, 2013, with respect to the Company’s Post-Effective Amendment No. 1 on Form S-3 to its Registration Statement on Form S-1 (333-183685). For your convenience, the
Staff’s comments are set forth in bold and followed by the Company’s response.
Comments
Information Incorporated by Reference, page 38
1.
We note that your registration statement incorporates by reference your annual report on Form 10-K for the year ended December 31, 2012. This filing does not
contain the Part III information that is required by Form 10-K. Please amend your registration statement, amend your Form 10-K filing, or file your definitive proxy statement to include the required Part III information. Your filing must be complete
before we take final action on the registration statement.
Jeffrey Riedler
Securities and Exchange Commission
April 25, 2013
Page 2
Response:
The Company expects to timely file its definitive proxy statement on April 29, 2013 which contains the Part III information of the Form 10-K. Thereafter, the Company
believes its filing would be complete.
* * * * *
Should you have any questions or clarifications of the matters raised in this letter please contact the undersigned at
(813) 229-7600.
Sincerely,
/s/ Mark A. Catchur
Mark A. Catchur
c: Michael Sullivan, Chief Financial Officer, Oragenics, Inc.